Track topics on Twitter Track topics that are important to you
Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...
* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima
More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More-
* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug
Biospectrum Celltrion's acquisition will help Teva boost its biosimilars portfolio [Read more]
Teva Pharmaceutical Industries is exploring the acquisition of South Korea-based Celltrion in its effort to expand its biosim -More-
The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More-
South Korean biotechnology company Celltrion has, according to The Korea Herald, submitted another biosimilar application to the European Medicines Agency (EMA).